Adjuvant Activities of Immune Response Modifier R-848: Comparison with CpG ODN
- 1 August 2000
- journal article
- research article
- Published by Elsevier in Cellular Immunology
- Vol. 204 (1), 64-74
- https://doi.org/10.1006/cimm.2000.1689
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvantsEuropean Journal of Immunology, 1997
- Immunomodulating and antiviral activities of the imidazoquinoline S-28463Antiviral Research, 1995
- Polyinosinic acid: polycytidylic acid promotes T helper type 1‐specific immune responses by stimulating macrophage production of interferon‐α and interleukin‐12European Journal of Immunology, 1995
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Interleukin‐12 profoundly up‐regulates the synthesis of antigen‐specific complement‐fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivoEuropean Journal of Immunology, 1995
- Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseasesImmunology Today, 1995
- T-cell subsets and cytokines in parasitic infectionsImmunology Today, 1992
- Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice.The Journal of Experimental Medicine, 1991
- Lymphokine Control of In Vivo Immunoglobulin Isotype SelectionAnnual Review of Immunology, 1990
- Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivativesBiochemical and Biophysical Research Communications, 1974